CoreValve

TCT 2021 | SURTAVI: buenas noticias para la válvula autoexpandible a 5 años

TCT 2021 | SURTAVI: Good News for the Self-Expandable Valve at 5 Years

After a 5-year followup, the transcatheter aortic replacement (TAVR) with the self-expandable valve has offered clinical outcomes similar to surgical aortic valve replacement (SAVR) outcomes for intermediate risk patients.&nbsp; As we already knew form the 2-year followup, the all-cause or disabling stroke rate at 5 years between TAVR and SAVR continued to be similar (31.3%<a href="https://solaci.org/en/2021/11/09/tct-2021-surtavi-good-news-for-the-self-expandable-valve-at-5-years/" title="Read more" >...</a>

Trombólisis local en tromboembolismo pulmonar

Device Evolution Also Impacts on Valve in Valve

TAVR to treat dysfunctional biological prosthetics (ViV) with the last generation self-expandable supra-annular prosthetic offers excellent results both clinical and hemodynamic. In addition, there were additional reductions of paravalvular regurgitation compared against the original models.&nbsp; The present registry published in JAHA is the most extensive to treat this issue and replicate outcomes from the clinical<a href="https://solaci.org/en/2021/10/21/device-evolution-also-impacts-on-valve-in-valve/" title="Read more" >...</a>

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

The FDA Approves a Third Device in the TAVR Race

The Portico self-expanding graft has obtained FDA approval and can now compete as one of the three options available in clinical practice for transcatheter aortic valve replacement (TAVR) in the United States. For the time being, its indication will have some restrictions: for example, it can only be used in high-risk patients (unlike CoreValve and<a href="https://solaci.org/en/2021/10/06/the-fda-approves-a-third-device-in-the-tavr-race/" title="Read more" >...</a>

Post-dilatación de válvulas autoexpandibles

Self-Expanding Valve in Extreme Surgical Risk After 5 Years

Patients with aortic stenosis and extreme surgical risk have extremely high mortality due to known comorbidities. The short-term benefit of transcatheter aortic valve replacement (TAVR) with self-expanding valve is clear, and it warrants the procedure in this challenging population. While elderly patients with comorbidities who are at extreme surgical risk might be eligible for TAVR,<a href="https://solaci.org/en/2021/06/24/self-expanding-valve-in-extreme-surgical-risk-after-5-years/" title="Read more" >...</a>

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

SCOPE I: Acurate NEO vs Sapien 3, no non-inferiority at one year?

The randomized controlled study SCOPE 1 failed to show significant differences at one year between the self-expandable Acurate neo and the balloon expandable Sapien 3.&nbsp; The SCOPE 1 (Safety and Efficacy of the Symetis ACURATE neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis) compared the balloon expandable Sapien 3 (which has probably more data) against<a href="https://solaci.org/en/2021/03/30/scope-i-acurate-neo-vs-sapien-3-no-non-inferiority-at-one-year/" title="Read more" >...</a>

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

New Valvular Heart Disease Guidelines with Key TAVI and Mitral Regurgitation Updates

Valvular heart disease management guidelines were updated last week by the AHA and the ACC.&nbsp; The last complete version had been published in 2014; therefore many of its recommendations have become obsolete before the latest evidence.&nbsp; The studies that made the FDA approve TAVI for low-risk patients are probably the most important incorporations. They also<a href="https://solaci.org/en/2021/01/07/new-valvular-heart-disease-guidelines-with-key-tavi-and-mitral-regurgitation-updates/" title="Read more" >...</a>

The Most Read Articles in Structural Heart Disease in 2020

The Most Read Articles in Structural Heart Disease of 2020

In this selection, we summarize for you the most important scientific news of 2020 in the field of structural heart disease. 01- Virtual ACC 2020 | COAPT: Better Quality of Life Translates into Harder End-Points After transcatheter mitral valve repair with MitraClip, the&nbsp;COAPT patients saw improved quality of life, better survival rate and fewer hospitalizations<a href="https://solaci.org/en/2020/12/17/the-most-read-articles-in-structural-heart-disease-of-2020/" title="Read more" >...</a>

lotus

Boston Scientific Discontinues Lotus Valve and Makes a New Bet

Mechanically-expanding valve Lotus Edge was discontinued worldwide, as recently informed by its manufacturer, Boston Scientific. This is a voluntary recall of all Lotus valve inventory, and the immediate suspension of the program. The United States Food and Drug Administration (FDA) approved Lotus Edge in 2019 for patients with severe aortic stenosis and high surgical risk.<a href="https://solaci.org/en/2020/12/03/boston-scientific-discontinues-lotus-valve-and-makes-a-new-bet/" title="Read more" >...</a>

TCT 2020 | Diferencias en stroke entre SAPIEN 3 y Evolut R que generan sorpresa

TCT 2020 | Surprising Differences in Stroke between SAPIEN 3 and Evolut R

One-year outcomes of the head to head trial between CoreValve Evolut R vs Sapien 3 showed a significantly higher difference in stroke vs. patients receiving the self-expanding valve (Sapien 3 6.9% vs Evolut R 1%; p=0.002). The SOLVE-TAVI randomized 2&#215;2 patients with severe aortic stenosis and high surgical risk to&nbsp;Sapien 3 or Evolut R and<a href="https://solaci.org/en/2020/10/21/tct-2020-surprising-differences-in-stroke-between-sapien-3-and-evolut-r/" title="Read more" >...</a>

TCT 2020 | Nueva información sobre el valor del FFR antes y después de la angioplastia

TCT 2020 | New Information about Pre and Post PCI FFR Value

The TARGET FFR and DEFINE-FLOW studies were presented at TCT 2020 which have offer a deeper perspective on the value of FFR, not only before but also after PCI. TARGET FFR The TARGET FFR included 260 patients randomized after angiographically successful PCI to an FFR guided optimization vs. blinded FFR assessment strategies.&nbsp; In the guided<a href="https://solaci.org/en/2020/10/21/tct-2020-new-information-about-pre-and-post-pci-ffr-value/" title="Read more" >...</a>

Top